The Counsyl Foresight Carrier Screen has been methodically designed to maximize detection of at-risk couples for serious, prevalent, and clinically-actionable diseases.
Kerri & DavidCounsyl Foresight Carrier Screen patients
Learn about Counsyl's latest advancement in carrier screening – the Counsyl Foresight Carrier Screen.
The Counsyl Foresight Carrier Screen is methodically designed to maximize at-risk couple detection for serious, clinically actionable, and prevalent diseases.
Counsyl Complete offers a comprehensive suite of support services designed to streamline and enhance practice workflow at every stage of genetic testing.
Elevate quality of care by offering expanded carrier screening to all patients regardless of family history or ethnicity.
The true goal of carrier screening is to detect at-risk couples of serious diseases. That’s why we’ve designed the Foresight Carrier Screen to maximize detection rates for the diseases that matter the most. Selecting a lab that enables you to offer the best test while streamlining the work associated with detecting more carriers allows you to confidently integrate expanded carrier screening into your practice.
Focusing on 175+ serious, clinically-actionable, and prevalent conditions ensures you are providing meaningful information to your patients.
View full disease list
Unmatched detection rates for the vast majority of genes on our panel means you can trust both positive and negative results.
Whether it’s automated results reporting and tracking, merged reports for couples, or on-demand genetic counseling, we support your practice where you need it.
175+ serious inherited conditions
Who to screen
Men and women planning to start a family
4mL blood, or saliva sample
Results in 2 weeks on average
The Foresight Carrier Screen is designed to maximize detection rates for the diseases that matter the most. Our experts evaluated >650 genes based on strict criteria in an effort to produce not simply more, but meaningful clinical information.Read more about our systematic panel design in Genetics in Medicine.
Full-exon sequencing provides a significant advantage over targeted sequencing.
Custom assays for prevalent, technically-challenging, difficult-to-sequence genes like 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH) substantially boosts at-risk couple detection.
Panel-wide deletion calling with select duplication calling for certain prevalent conditions to further boost sensitivity.
Real-time curation combines automation with manual investigation to classify variants.Learn more about the Foresight Carrier Screen
Selecting a lab that enables you to offer the best test while streamlining the work associated with detecting more carriers allows you to confidently integrate expanded carrier screening into your practice.
We make it easy to qualify, educate, and order testing for your patients.
We strive to make screening accessible for all patients who need it.
We automate results delivery and follow up with patients to save your practice time.
Our board-certified genetic counselors are available on-demand for all patients to ensure results are understood.
Carrier screening is used to identify couples who are at risk of passing inherited disorders to their children. Traditionally, carrier screening has been offered to patients based on their ethnic background or family history.
However, this approach can miss couples at risk of having a pregnancy affected by a genetic disease.
In 2017, the American College of Obstetrics and Gynecology (ACOG) recognized expanded carrier screening as an acceptable screening strategy. Offering ECS routinely, regardless of family history or reported ethnicity, improves outcomes for all patients.
In fact, the total risk of serious disorders identified through ECS is higher than the incidence of routinely screened for conditions.
Submit your information and we will reach out to you directly.Offer Counsyl at Your Clinic
References:1. Lazarin GA, Hawthorne F, Collins NS, et al. Systematic Classification of Disease Severity for Evaluation of Expanded Carrier Screening Panels. PLoS One 2014; 9:e114391 2. Blythe SA, et al. Advances in the diagnosis and management of cystic fibrosis. Clin Biochem 1984; 17(5):277-283. 3. Haque IS, Lazarin GA, Kang HP, Evans EA, Goldberg JD, Wapner RJ. Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening. JAMA. 2016; 316(7):734-742. 4. de Graaf G, Buckley F, Skotko BG. Estimates of live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet 2015; 167(4):756-767. 5. Cragan JD, Roberts HE, Edmonds LD, et al. Surveillance for ancephaly and spina bifida and the impact of prenatal diagnosis--United States, 1985-1994. MMWR CDC Surveill Summ 1995 Aug 25; 44(4):1-13. 6. Cystic Fibrosis Foundation Patient registry 2012 annual data report. Bethesda, Maryland. ©2013 Cystic Fibrosis Foundation